Semaglutide improved heart filling in obesity-related heart failure
Semaglutide improved how much the heart’s upper left chamber stretched by 5.7 percentage points versus placebo over 52 weeks in a 49-person trial substudy.
Our read
Interventions- Studied:
- Randomized trial in 49 people (52 weeks, placebo-controlled, registered NCT05371496)
- In the record:
- The 678th paper on semaglutide with results in people; 1,706 on record in all.
- Why it’s aging research:
- It studies an intervention with evidence of extending healthy life.
Editor of record: Boris Djordjevic · AgingResearch.News
Forty-nine participants with obesity and heart failure with preserved ejection fraction—a form of heart failure in which the heart pumps out a normal proportion of its blood—underwent heart scans in a randomized trial substudy. Of these, 28 were female; 33 received semaglutide and 16 received placebo. Magnetic resonance scans took place at the start and after 52 weeks.
Semaglutide improved left atrial reservoir strain, a measure of how much the heart’s upper left chamber stretches as it fills. It also improved a measure of how quickly the lower left chamber filled between beats. Both improvements were associated with lower estimated pressure in the upper left chamber during exercise. Semaglutide also reduced lower left chamber muscle mass and improved right-sided heart function.
Why it matters
Heart failure is an age-related condition. The authors suggest that improvements in heart muscle function may contribute to semaglutide’s effects on pressures during exercise.
Caveats
These imaging and pressure results do not show whether semaglutide reduced hospitalizations or deaths in these 49 participants with obesity-related heart failure. The abstract does not give the dose or adverse-event results.
Comments
Be the first to comment.